Abstract 170P
Background
Monocyte-derived macrophages (mo-macs) and polymorphonuclear leukocytes (PMNs) are abundant in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), limiting response to immune checkpoint blockade (ICB) by promoting an immunosuppressive tumor microenvironment (TME). Preclinical work shows that tumor-derived CCR2 ligands and IL8 play a key role in recruiting mo-macs and PMNs, respectively, to the TME. Disrupting these signaling pathways augments ICB in mouse models, but clinical benefit has yet to be observed.
Methods
This phase IIa trial assessed the efficacy of BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8) administered with nivolumab (NIVO) over 4 weeks prior to resection. NSCLC patients were treated with NIVO and CCR2/5i (arm A) or NIVO and anti-IL8 (arm B). HCC patients were treated with NIVO (arm C), NIVO and CCR2/5i (arm D), or NIVO and anti-IL8 (arm E). Primary endpoints were major pathologic response (≤10% viable tumor) for NSCLC and significant tumor necrosis (>70% necrosis) for HCC. Secondary endpoints were safety/tolerability, time to surgery (TTS), and radiographic response.
Results
36 patients were enrolled from March 2020-August 2023; 14 were treated with NIVO and CCR2/5i, 16 with NIVO and anti-IL8, and 6 with NIVO. CCR2/5i and anti-IL8 were safe/tolerated (dose-limiting toxicities or grade 3/4 treatment-related adverse events). 32 of 36 patients underwent resection (mean TTS of 34.8 days). 3 patients met the primary endpoints: 2 in arm B and 1 in arm D. In patients treated with CCR2/5i, serum concentration of CCR2/5 ligands increased, and number of circulating monocytes decreased, after treatment. In patients treated with anti-IL8, serum concentration of IL8 decreased after treatment; however, number of circulating PMNs was not affected. Tissue analysis with scRNA-seq and multiplex imaging is ongoing to elucidate the biologic effects of these agents.
Conclusions
Although CCR2/5i and anti-IL8 appear to be biologically active and exert effects on chemokine levels, they fail to significantly augment the role of ICB in the preoperative setting, contrary to preclinical evidence.
Clinical trial identification
NCT04123379.
Legal entity responsible for the study
The authors.
Funding
CIMAC-CIDC, PACT.
Disclosure
S. Gnjatic: Financial Interests, Personal and Institutional, Funding, Unrelated to Current Work: Regeneron Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono, Pfizer, and Takeda. M. Merad: Financial Interests, Personal, Advisory Board: Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc., Owkin Inc., Larkspur Inc., Innate Pharma Inc., DBV Inc., Pionyr Inc., OSE Inc., Genenta Inc.; Financial Interests, Personal, Stocks/Shares: Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc., Owkin Inc., and Larkspur Inc.; Financial Interests, Personal and Institutional, Funding: Regeneron Inc. and Boehringer Ingelheim Inc. T.U. Marron: Financial Interests, Personal, Advisory Board: Rockefeller University, Regeneron Pharmaceuticals, AbbVie, Bristol Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus, and Astellas; Financial Interests, Personal and Institutional, Funding: Regeneron, Bristol Myers Squibb, Merck, and Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display